🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“Always rule out bladder cancer when patients are presenting with over active bladder amd not respond to symptomatic treatment.” MD Van den Broeck Thomas presenting at #BAU21 BVU Société Belge d'Urologie European Association of Urology (EAU) steven joniau Siska Van Bruwaene Pieter Uvin “use narrow band imaging/blue light & cytology”

WPRT or PORT for pN1 PCa: first results of the PROPER trial reveal: - difficulties to recruit patients - no pelvic recurrences but more acute grade 2 GI toxicity with WPRT StichtingtegenKanker

Stuck on the island of Milos (no boats back). But ready for #PROSCA22 Mirrors of Medicine 💪

Some Stampede high risk patients might be cured with surgery alone instead of ‘suffering’ 2 years of intensified hormonal treatment. #PROSCA22 steven joniau excellent talk

D2 #PROSCA22 in beautiful Athens silke gillessen outlines the evidence for #docetaxel in #mHSPC Is volume of disease important? Does it matter if synchronous v metachronous disease? Triple v doublet therapy? Mirrors of Medicine Nick James also on @Prof-Nick-James.bsky.social

Nick James also on @Prof-Nick-James.bsky.social on the association between volume & radiotherapy in #metastaticprostatecancer Is 4 the magic no for mets? How important is LN burden? Can men with mets be cured? 🤔 #PROSCA22 Mirrors of Medicine

Amit Bahl warning to perform imaging in mCRPC even when PSA is stable. #PROSCA22

Just when you thought to grasp oligo-metastatic disease …Julia Murray helping to see the light #PROSCA22

Late breaking abstracts #ASTRO22 - Chad Tang, MD EXTEND trial; oligometastatic #prostatecancer. Intermittent ADT + SABR versus ADR alone extends PFS, but importantly time men enjoy off ADT in the long term (eugonadal PFS). Important patient centric endpoint! 👏🏽⭐️ OncoAlert #pcsm

When low-volume on conventional imaging goes into high-volume on next-generation imaging in #mHSPC - treat like low-volume. #APCCC22 presentation by Karim Fizazi Gustave Roussy. #ReadNow on UroToday > bit.ly/3RgVCLs Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin

Lymphedema after prostate cancer treatment? For many, it remains the forgotten vascular disease. 👉 Find out in our systematic review mdpi.com/1953218 #mdpicancers via Cancers MDPI steven joniau Wouter Everaerts Lisa Moris

Check out our latest paper on "Quality Control Indicators for TURBT" #bladdercancer European Urology Oncology authors.elsevier.com/c/1gHHb9Cfv-t-… CABLE @TimMuilwijk Frank Van der Aa steven joniau Yannic Raskin Siska Van Bruwaene @KathyVanderEeckt @BenVanCleynenbreugel Cedric Jorissen UZ Leuven @VznkuL

15yr f/u for #ProtecT_Trial just out! •n=1610 •1/3 IR or HR by NCCN criteria •n=45 DS deaths (AM17:RP12:RT16) •n=104 mets (AM51:RP26:RT27) •n=151 started ADT (AM69:RP40:RT42) •62% of AS cross over to radical Surprised? Or no surprises?? #EAU23 #Oxford_Urology BAUS

ProtecT 15 yr: ⁦Freddie Hamdy⁩ taking on misconceptions, and conclusions. #eau23 Thoughts #pcsm??

Guess this is key slide from Freddie's talk. It's given me a bit of an existential crisis over past 36hrs Should we approach all localised #ProstateCancer like we now do salvageRT? i.e. put EVERYONE on surveillance, then only treat those who 'progress'?? (1/3 were T3!) #EAU23

🔬ePLND in #BladderCancer 🏥 😞 More harm. ❌Zero benefit 📚Level I evidence from SWOG Cancer Research Network👩‍⚕️👨‍⚕️ meetings.asco.org/abstracts-pres… (tnx Kevin Ginsburg for alway being the first to find the good stuff!) #ASCO23 ASCO

🔬💊 #TherapeuticNodeYield ➡️ #WillRogers 🤠 + #BiasMirage 🔮 as long anticipated pubmed.ncbi.nlm.nih.gov/36573245/ Kevin Ginsburg #ASCO23

Siska Van Bruwaene Wouter Everaerts Piet Ost Shane Kronstedt It’s quite amazing!! PLND appears to have disappeared from the updated Prostate Cancer #EAUGuidelines! Now aligns with practice in Australia 10 years into the PSMA era #EAU24